Title page

Fibrinogen and hypertension are key factors associated with tremor relieve and recurrence in the ET patients subjected with MRgFUS thalamotomy

Authors and affiliations

Jiaji Lin [1, 2], Haoxuan Lu [1], Dekang Zhang [1], Xianbing Bian [1], Jianxing Hu [1], Longsheng Pan [3†], Xin Lou [1†].

1 Department of Radiology, Chinese PLA General Hospital/Medical School of Chinese PLA, No.28 Fuxing Road, Beijing, 100853, China

2 Department of Neurology, The Second Affiliated Hospital of Air Force Medical University, Xi'an, 710038, China

3 Department of Neurosurgery, Chinese PLA General Hospital/Medical School of Chinese PLA, No.28 Fuxing Road, Beijing, 100853, China

[†]**Correspondence to:**

Xin Lou, Department of Radiology, Chinese PLA General Hospital/Medical School of Chinese PLA, 28 Fuxing Road, Beijing, 100853, China. Tel: 86-10-66936620. Fax: 86-10-68155902. E-mail: louxin@301hospital.com.cn. & Longsheng Pan, Department of Neurosurgery, Chinese PLA General Hospital/Medical School of Chinese PLA, 28 Fuxing Road, Beijing, 100853, China. Tel: 86-10-66936666. Fax: 86-10-68155910. E-mail: panls301@163.com.

Article type

Original research

Conflict of interest

The authors declare that they have no competing interests.

Author contributions

Conceptualization: XL, LSP, JJL; Methodology: JJL, HXL, DKZ, XBB, JXH; Investigation: DKZ, XBB, JXH; Visualization: JJL, DKZ; Supervision: LSP, XL; Writing-original draft: JJL, XPK, JS; Writing-review & editing: LSP, XL.

Acknowledgments

This research was supported by National Natural Science Foundation of China 82151309, 81825012 and 81730048 to XL as well as China Postdoctoral Science Foundation 2022T150788 to JJL.

Abstract (280 words)

Background There were variable differences and declines in efficacy of magnetic resonance guided focused ultrasound (MRgFUS) thalamotomy, but whether the clinical status of these patients was involved was still unknown.

Methods We retrospectively reviewed the tremor symptoms and clinical variables (at hospitalization) of 59 essential tremor (ET) patients subjected with MRgFUS thalamotomy. Patients were categorized by the short-term tremor relieve, tremor recurrence within 12 months and long-term maintenance outcome. Multivariate logistic regression was used to screen independent factors and construct the nomogram. Additional harmaline-induced ET model in male ICR mice were employed, we evaluated the possible anti-tremor effects of fibrinogen knock-out.

Results MRgFUS thalamotomy resulted in significant tremor relieve, multivariate analysis suggested fibrinogen (OR = 0.182, 95% CI = 0.042-0.796,) and monocyte count (OR = 0, 95% CI = 0-0.001) were independently associated with better short-term tremor relieve (>75%) at 1-month postoperatively. A total of nine ET patients (15.254%) experienced significant tremor recurrence. Admission systolic blood pressure (OR = 1.013, 95% CI = 1.010-1.062), hypertension comorbidity (OR = 2.163, 95% CI = 1.412-53.565) and fibrinogen (OR = 1.620, 95% CI = 1.047-24.376) independently contributed to tremor recurrence. There were 15 ET patients (25.424%) sustained long-term and effective tremor control. Only admission systolic blood pressure was the independent prognostic factor (OR = 0.880, 95% CI = 0.785-0.987) for this favorable outcome. The nomograms were established for better tremor relieve and tremor recurrence and have excellent performance as the AUCs were 0.829 and 0.853 (bootstrap repetition = 1000). Finally, FGB knock-out significantly suppressed harmaline-induced tremor *in vivo* (*P* < 0.001).

Conclusion Fibrinogen and hypertension are key factors associated with tremor relieve and recurrence in the ET patients subjected with MRgFUS thalamotomy.

Main text

1. Introduction

Magnetic resonance guided focused ultrasound (MRgFUS) thalamotomy targets the ventral intermedius nucleus (Vim) of the thalamus and has been shown to be safe and effective to treat tremor diseases [1]. Propelled by advancements in phased-array transducers, focused ultrasound (FUS) procedures enable precise localization of the target site before the lesion creation. Initial deposition of thermal energy, below the threshold for tissue lesioning, can be executed at the target site. Biofeedback, observed as tremor alleviation, is then utilized to confirm or adjust the target location, all while monitoring the patient for adverse effects. Upon finalizing the target site, sonication procedures continue until a specific temperature is achieved, resulting in irreversible thermal coagulation. Thalamotomy by MRgFUS touts numerous advantages, including minimal invasiveness, preservation of surrounding tissue, and precise millimeter-level targeting [2]. Numerous studies have substantiated that MRgFUS thalamotomy not only delivered tremor relieve exceeding 78% for medically refractory essential tremor (ET) and over 85% improvement for tremor-dominant Parkinson's disease (PD) [2], but also saved about 68.28% expenses and 0.03 additional quality-adjusted life-years (QALYs) per patient [3]. These breakthroughs have resulted in the wide approval of MRgFUS devices for addressing movement disorders by multiple regulatory agencies.

However, one of the main criticisms regarding MRgFUS thalamotomy is the potential loss of effectiveness and tremor recurrence in the long-term course. Early experiences show that initially successful MRgFUS thalamotomy can loss effectiveness in up to 23.2% of cases within the first year after FUS without any identifiable cause [4]. These tremor relapse, on one hand, has been widely thought to be related to the inappropriate practice of MRgFUS treatment, such as inaccuracy of targeting, insufficient lesion size, resolution of perilesional edema and so on [5]. Bruno et al. identified patients with tremor relapse from a series of 79 treatments and found a more frequent eccentric position of the dentato-rubro-thalamic tract or smaller thalamotomy lesions in patients with tremor relapse [6]. On the other hand, the disease development and long-term neuroplasticity alteration after brain lesion may also contribute to tremor recurrence. Hori et al. retrospectively examined radiological data of 12 ET patients and found that 4 patients with significant tremor recurrence presented dynamic reconstruction of relative fractional anisotropy in the Vim of thalami [7]. However, it seems that most analyses have always overlook the clinical status of these patients. As a minimal lesion therapy, MRgFUS thalamotomy is likely to share similar risk factors that affect the trajectory of disability and recovery after brain injury, including hypertension, diabetes and hyperlipemia [8]. To this end, we retrospectively collected the clinical features of ET patients subjected with MRgFUS thalamotomy and try to determine predictive factors for their outcomes.

2. Methods

2.1 Study population of unilateral MRgFUS thalamotomy

Demographic and clinical information for this observational, retrospective, single-center study was collected from Chinese PLA General Hospital. It was approved by the institutional review board and the independent scientific advisory committee at Chinese PLA General Hospital. The data were anonymous, and the requirement for informed consent was therefore waived. Between 2018 and September 2023, more than 100 patients admitted fulfilling diagnostic criteria for medically refractory ET and received unilateral MRgFUS thalamotomy in Chinese PLA General Hospital. All subjects had unilateral tremor manifestations on one extremity and unilateral MRgFUS thalamotomy in contralateral Vim was performed in a 3T MRI suite (Discovery 750, GE Healthcare, USA) using the ExAblate Neuro focused ultrasound system as previous reports (InSightec, Israel). This procedure was consistent with those in previous reports [9]. Briefly, the patient's head was fixed, and low-power sonication was used for the initial target ablation and adjusted based on real-time patient feedback. After final target was determined, the energy was increased so that the target tissue ablation temperature reached approximately 55-60°C. Tremor assessments were performed pre-operatively, and at 1-month, 3-month, 6-month, and 12-month postoperatively to evaluate the effectiveness of unilateral MRgFUS thalamotomy. The medical records of all these patients were carefully reviewed, many patient records were excluded due to incomplete follow-up of postoperative tremor assessments caused by the Covid-19 pandemic. Finally, a total of 59 records were enrolled for present retrospective study with complete tremor evaluation. No patients experienced significant postoperative complications and severe side effects during this period.

The clinical variables of these 59 patients were collected at hospitalization for MRgFUS thalamotomy, including demographic characteristics (age, gender, body mass index, admission systolic blood pressure, admission diastolic blood pressure, admission pulse rate), common comorbidity (hypertension, diabetes, hyperlipemia), hematological analysis (hemoglobin, red blood cell, white blood cell, neutrophil, lymphocyte, monocyte, eosinophil, basophil, hematocrit, mean corpuscular volume, mean corpusular hemoglobin, mean corpusular hemoglobin concerntration, red blood cell volume distribution, platelet, mean platelet volume), coagulation function (thrombin time, activated partial thromboplastin time, prothrombin time, prothrombin activity, international normalized ratio, fibrinogen), lipids Profile (cholesterol, triglyceride, apolipoprotein A1, apolipoprotein B, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, serum lipoprotein a), blood biochemistry (alanine aminotransferase, aspartate aminotransferase, total protein, serum albumin, total bilirubin, direct bilirubin, total bile acids, homocysteine, alkaline phosphatase, gamma-glutamyltransferase, glucose, urea, serum creatinine, serum uric acid, lactate dehydrogenase, total iron-binding capacity, creatine kinase, creatine kinase isoenzyme, serum calcium, inorganic phosphorus, serum magnesium, serum kalium, serum sodium, serum chloride, serum carbon dioxide, serum superoxide dismutase, phospholipid, glycosylated serum protein, serum cystatin C, serum sialic acid, glycated albumin, α-L-fucosidase, glycholic acid).

2.2 Clinical tremor assessment and criterion

Tremor performance was assessed in off-medication state using Clinical Rating Scale for Tremor (CRST) ratings preoperatively and at 1-month, 3-month, 6-month, and 12-month after MRgFUS thalamotomy, including CRST-A assesses tremor location and amplitude, CRST-B assesses tremor when

performing specific motor tasks, and CRST-C assesses functional disability due to tremor [9]. Primary hand tremor score contralateral to the Vim lesion was measured using a derived subscale composed of CRST-A (three items on a scale of 0-4 for each: rest, posture, and action components of hand tremor) and CRST-B (five tasks on a scale of 0-4 for each: handwriting-dominant hand only, drawings and pouring). The relative hand tremor score ratio was calculated with the formula: postoperative scores / preoperative scores $\times$ 100%. The control ratio of hand tremor score was calculated with the formula: (postoperative scores - preoperative scores) / preoperative scores $\times$ 100%.

Unilateral MRgFUS thalamotomy resulted in significant tremor relieve immediately. In order to ensure the reliability of the treatment results, the tremor assessment at 1-month postoperatively was used for the measurement of short-term tremor improvement. According to the criterion of $\geq$ 50% control ratio of hand tremor score [10], all included patients presented a good effectiveness to MRgFUS thalamotomy with the control ratio ranged from 65.196% to 100% at 1-month postoperatively. In order to study the factors affecting effectiveness, we assigned the patients with the control ratio >75% in the better tremor relieve group. Moreover, in our present study, tremor recurrence was defined as new onset or worsening of symptoms occurring after an initial improvement for 1 months, in which hand tremor score of other postoperative timepoints (3-month, 6-month, and 12-month postoperatively) increased by 8 points and 25% compared with 1-month postoperatively. In order to study factors associated with tremor recurrence, we divided these patients into the with/without tremor recurrence groups based on whether they had tremor recurrency at 12-month postoperatively. Furthermore, a long-term stabilization of tremor relieve after MRgFUS thalamotomy has always considered as favorable outcome. This stabilization was defined that the control ratio of hand tremor score was higher than 75% at all timepoints postoperatively, and the alteration of hand tremor scores at 3-month, 6-month, and 12-month postoperatively timepoints was less than 5% and 3 points compared to that of 1-month postoperatively. In order to study factors associated with favorable outcome, we further divided these patients into the favorable outcome group and poor outcome group based on whether they had long-term stabilization of tremor relieve within 12 months after MRgFUS thalamotomy.

2.3 Allen brain atlas for transcript distributions

Neuroanatomically precise, genome-wide maps of transcript distributions are critical resources to study genomic genetic architecture. Allen Institute for Brain Science offer the first anatomically and genomically comprehensive three-dimensional human brain map constructed by the brains of six human donors with no history of psychiatric or neuropathological disorders (referred as Allen Human Brain Atlas (AHBA)) [11], as well as mice brain map (referred as Allen Mouse Brain Atlas (AMBA)) [12]. We extracted human brain gene transcriptome data were from the AHBA, which contains a database of 20,737 gene expression levels represented by 58,692 probes. All these gene expressions were matched for 274 ROIs of the Brainnetome atlas using the toolbox Abagen [13]. The microarray expression data were combined across donors, and the representative expressions were calculated for each brain regions, including cerebral cortex (n = 218), basal ganglia (n = 12), thalamus (n = 16), cerebellum (n = 27). Moreover, we also extracted in-situ hybridization (ISH) data for fibrinogen-related transcripts, including

fibrinogen alpha (FGA) (https://mouse.brain-map.org/experiment/show/68442907), fibrinogen beta (FGB) (https://mouse.brain-map.org/experiment/show/68638095), and fibrinogen gamma (FGG) (https://mouse.brain-map.org/experiment/show/576438). The detail experiment procedure and antisense probe information could be found in above sites.

2.4 Tremor induction and measurement in vivo

Animal care and experimental procedures were in accordance with institutional and NIH protocols and guidelines, and all studies were approved by the Committee on the Ethics of Animal Experiments of Air Force Medical University. Male C57BL/6 mice aged 6-8 weeks were obtained from the Laboratory Animal Center of the Air Force Medical University. Male C57BL/6Smoc-Fgb^{em1Smoc} mice (Cat. NO. NM-KO-200199) aged 6-8 weeks were purchased from Shanghai Model Organisms Center, Inc. All mice were maintained under SPF conditions. Mice were housed with a 12□h dark/light cycle, humidity of 40-70%, ambient temperature of 20-26□°C and enough supplement of food and water.

Tremor was induced by intraperitoneal injection of harmaline (Sigma-Aldrich, USA). Mice were moved with their home cages to a behavior room and acclimated there for at least one hour before testing. The frequency and intensity of tremor were measured and analyzed using a force-plated accelerometer (Tremor Monitor, San Diego Instruments, USA), which can accurately identify tremor activity from ambulatory/stereotyped movements and global motion activity. Each mouse was placed in the chamber for acclimatization, and then the baseline motion power was recorded for 10 min before administration.

Each raw trace of the tremor activity was filtered and converted to power spectra of frequency by a fast

Fourier transform on each frame of the experiment using python engine. To quantify the difference in tremor performance of each mouse, the tremor activity ratio was measured as the ratio of the tremor motion power (at tremor frequency bandwidth of 8-15 Hz) over the total motion power (at full motion spectrum of 0-30 Hz) within 10 min duration. The overall tremor activity was expressed by the area under curve (AUC) derived and was normalized by the averaged baseline. The experiment was performed over five consecutive days.

2.5 Statistical analysis

Most computations were performed in the R engine or SPSS 23.0. Categorical data were presented as number with percentage and continuous data as median with standard error (SD). Pearson correlation was used to assess the association between clinical variables and tremor symptoms. Intergroup di□erences were evaluated by chi-square or Fisher exact tests for categorical data and by Student t-test or Mann-Whitney U test for continuous data with normal or skew distribution, with False Discovery Rate (FDR) correction if appropriate. Binary logistic regression analyses were performed to identify predictors for tremor control, tremor recurrence or a favorable clinical outcome. Variables with $P < 0.05$ from the univariate regression analysis were included in the subsequent multi-variate analysis and to construct the nomogram. Receiver operating characteristic (ROC) curves were plotted to calculate the AUCs, confidence interval by the bootstrap approach (bootstrap repetition = 1000) to discriminate the

performance of the nomogram. In addition, we measured calibration analysis by bootstrap approach (bootstrap repetition = 1000) and Hosmer-Lemeshow test to assess the agreement of nomogram. A P value < 0.05 was used as the criterion for a significant statistical difference.

2.6 Data availability

Anonymized data will be made available by request from the corresponding author.

3. Results

At the preoperative baseline (Pre-op), the mean age of these 59 patients was 62.877 ± 9.885 years and the sex ratios (male:feamle) were 42:17. Among them, average disease duration were 20.741 ± 10.870 years and mean skull density ratio (SDR) were 0.509 ± 0.113. Of 50 patients with family enquire available, 41 of them (82.000%) had a family history of ET. PHQ-9 and MMSE examinations were found in 55 and 37 patients' records, with scores of 2.655 ± 3.122 and 27.722 ± 1.814 respectively. There were significant tremor manifestations on the right extremity in 55 ET patients and the left extremity in 4 patients. Their hand tremor scores were 21.810 ± 4.169 and CRST-total scores were 60.517 ± 13.242. We tried to analyze whether the clinical baseline variables were correlated with tremor ratings at baseline, and there was no significant result after FDR verification. We also studied the clinical baseline variables based on ET disease duration, and the results showed that patients with disease duration less than 10 years (n = 8) had much higher in homocysteine ($t = 4.854$, $P_{FDR} = 0.001$) and fibrinogen ($t = 3.357$, $P_{FDR} = 0.049$).

3.1 Factors associated with better tremor relieve in ET patients right after unilateral MRgFUS thalamotomy

Unilateral MRgFUS thalamotomy resulted in significant tremor relieve (LMM: $P_{for\ trend} < 0.001$ for hand tremor score and all CRST ratings) (Figure 1A). Their hand tremor scores decreased to 4.368 ± 3.806 points (control ratio = $80.694 \pm 15.498\%$, $P < 0.001$ compared with Pre-op) and CRST-total scores decreased to 20.948 ± 11.657 (control ratio = 66.711 ± 14.639 %, $P < 0.001$ compared with Pre-op) at 1-month postoperatively.

ET patients obtained different benefits right after MRgFUS thalamotomy. There were 39 patients with significantly better efficiency in tremor relieve (control ratio > 75%) right after treatment, which were assigned for the group comparisons for clinical factors. As shown in Table 1, these patients with better tremor relieve had much lower basophil count ($t = -2.974$, $P = 0.004$), lower alkaline phosphatase ($t = -2.743$, $P = 0.008$), lower monocyte count ($t = -2.312$, $P = 0.025$), lower fibrinogen ($t = -2.309$, $P = 0.025$), lower total protein ($t = -2.275$, $P = 0.027$) than those without better tremor relieve. All factors with significant differences were examined using univariate logistic regression model, and it was found that alkaline phosphatase (odds ratio [OR] = 0.956, 95% CI = 0.922-0.992, $P = 0.016$), basophil count (OR = 0, 95% CI = 0-0.001, $P = 0.026$), monocyte count (OR = 0, 95% CI = 0-0.011, $P = 0.027$), fibrinogen (OR = 0.292, 95% CI = 0.096-0.886, $P = 0.030$), total protein (OR = 0.891, 95% CI = 0.794-0.999, $P = 0.044$) were negatively associated tremor relieve efficiency (Table 2). Subsequent multivariate analysis indicated that fibrinogen (OR = 0.182, 95% CI = 0.042-0.796, $P = 0.024$) and

monocyte count (OR = 0, 95% CI = 0-0.001, P = 0.014) were independently associated with tremor relieve efficiency (Table 2).

We then used these two factors to establish an individualized prediction nomogram, which can calculate the total point for each ET patient subjected with unilateral MRgFUS thalamotomy and converted it to predicted probabilities of better tremor relieve efficiency (Figure 1B). The ability of our nomogram to discriminate the patients with tremor recurrence was excellent as the AUC was 0.820 (95% CI = 0.690-0.919, bootstrap repetition = 1000) (Figure 1C). Besides, the P-values of the Hosmer-Lemeshow test is 0.542 and the result of the calibration curve by the bootstrap approach (bootstrap repetition = 1000) indicated our model had a good agreement.

3.2 Factors associated with tremor recurrence in ET patients with unilateral MRgFUS thalamotomy

As indicated in Figure 1A, a slight decrease in tremor control ratio could be observed at later follow-up of 12 months, patients' hand tremor scores decreased to 6.655 ± 5.842 points (control ratio = $70.484 \pm 23.982\%$, $P < 0.001$ compared with Pre-op) and CRST-total scores decreased to 26.017 ± 17.564 (control ratio = $58.712 \pm 23.749\%$, $P < 0.001$ compared with Pre-op) at 12-month postoperatively. Significant recurrence of tremors occurred in some patients.

Alteration in tremor manifestations were assessed for each patient after unilateral MRgFUS thalamotomy. There were three ET patients experienced significant tremor recurrence at 6-month postoperatively (Figure 2A). A total of nine ET patients (15.254% of 59 patients) finally experienced significant tremor recurrence at 12-month postoperatively, of which one patient almost completely returned to the preoperative state (Figure 2A). We divided these patients into a tremor recurrence group, and ET patients with tremor recurrence is different from those without tremor recurrence in a number of respects, including a younger age ($t = 2.293$, $P = 0.026$), admission systolic blood pressure ($t = 2.103$, $P = 0.040$), a more frequent comorbidity of hypertension ($X^2 = 7.445$, $P = 0.006$), higher fibrinogen ($t = 2.293$, $P = 0.028$), higher serum magnesium ($t = 2.070$, $P = 0.043$), higher Lp (a) ($t = 2.052$, $P = 0.045$) than those without tremor recurrence (Table 3). Further univariate analysis identified age (OR = 1.143, 95% CI = 1.012-1.290, $P = 0.032$), admission systolic blood pressure (OR = 1.053, 95% CI = 1.036-1.075, $P = 0.046$), hypertension comorbidity (OR = 7.7, 95% CI = 1.427-41.557, $P = 0.018$), fibrinogen (OR = 4.255, 95% CI = 1.091-16.597, $P = 0.037$), serum magnesium (OR = 6×10^5, 95% CI = 1.076-4×10^{11}, $P = 0.049$) were positively associated tremor recurrence (Table 4). Compared to univariate analysis, subsequent multivariate analysis indicated that admission systolic blood pressure (OR = 1.013, 95% CI = 1.010-1.062, $P = 0.049$), hypertension comorbidity (OR = 2.163, 95% CI = 1.412-53.565, $P = 0.020$) and fibrinogen (OR = 1.620, 95% CI = 1.047-24.376, $P = 0.044$) were independent associations with tremor recurrence (Table 4).

Then, admission systolic blood pressure, hypertension comorbidity and fibrinogen were applied to develop a predictive nomogram for individualized probabilities of tremor recurrence (Figure 2B). It showed that this nomogram could effectively discriminate the patients with tremor recurrence with the high AUC of 0.829 (95% CI = 0.965-0.963, bootstrap repetition = 1000) (Figure 2C). Moreover, the

P-values of the Hosmer-Lemeshow test is 0.498 and the result of the calibration curve by the bootstrap approach (bootstrap repetition = 1000) indicated our model had a good agreement.

3.3 Factors associated with long-term favorable outcome in ET Patients with unilateral MRgFUS thalamotomy

In addition to the obvious tremor recurrence, other patients also showed varying degrees of fluctuations in tremor relieve at different timepoints post MRgFUS thalamotomy. So that, we tried to further explore the clinical factors that contribute to the maintenance of long-term and effective tremor control.

Within four tremor assessments (1-month, 3-month, 6-month, and 12-month postoperatively), 15 ET patients (25.424% of all) sustained a favorable outcome of long-term and effective tremor control after unilateral MRgFUS thalamotomy (Figures 3A). Table 5 outlines the comparisons between ET patients with/without favorable outcome. It significantly showed that a younger age ($t = 2.067$, $P = 0.043$), lower admission systolic blood pressure ($t = 4.303$, $P < 0.001$), lower admission diastolic blood pressure ($t = 2.586$, $P = 0.012$), less alkaline phosphatase ($t = 2.478$, $P = 0.016$), less apolipoprotein B ($t = 2.435$, $P = 0.018$) could be found in these patients with favorable outcome than patients without favorable outcome. The statistical difference of fibrinogen was very close to the statistical threshold (favorable outcome *vs.* poor outcome: $t = 1.837$, $P = 0.071$). Accordingly, in the univariate logistic regression analysis, admission systolic blood pressure (OR = 0.881, 95% CI = 0.816-0.952, $P = 0.001$), admission diastolic blood pressure (OR = 0.925, 95% CI = 0.867-0.987, $P = 0.019$), apolipoprotein B (OR = 0.003, 95% CI = 0-0.512, $P = 0.027$), alkaline phosphatase (OR = 0.949, 95% CI = 0.908-0.993, $P = 0.022$) were negatively associated with favorable outcome (Table 6). Additional univariate analysis found that patient age and fibrinogen also had significance close to the threshold of 0.05 (age: OR = 0.941, 95% CI = 0.885-1.001, $P = 0.054$; fibrinogen: OR = 0.326, 95% CI = 0.094-1.132, $P = 0.078$). Moreover, multivariate analysis suggested that admission systolic blood pressure was the only independent prognostic factor (OR = 0.880, 95% CI = 0.785-0.987, $P = 0.029$) for favorable outcome (Table 6). ROC curves of the model predicting favorable outcome were presented in Figures 3B. The AUCs of the model predicting probabilities of favorable outcome were 0.853 (95% CI = 0.667-0.867, bootstrap repetition = 1000).

3.4 Suppression of Fibrinogen beta knock-out on harmaline-induced tremor in vivo

In above studies, we found that fibrinogen was strongly associated with disease duration, tremor control, and tremor recurrence in ET patients, which suggested it may be closely related to the pathogenesis of ET. So that we matched the three major gene expressions of fibrinogen (fibrinogen alpha (FGA), beta (FGB) and gamma (FGG)) from the AHBA microarray for the Brainnetome atlas. It showed that, in the human brain, the expressions of FGA and FGG were far from intensity-based filtering of 0.3, while FGB obtained a high expression, especially in the cerebellum (cerebellum *vs.* cerebral cortex: $P < 0.001$; cerebellum *vs.* basal ganglia: $P < 0.001$; cerebellum *vs.* thalamus: $P < 0.05$) (Figures 4A). To further verify this result, we collected ISH data from AMBA mice brain. The stainings also showed that only FGB was highly expressed in the mice brain, also especially in the cerebellum (Figures 4B).

Curious about the role of FGB in the pathogenesis of ET tremor, both normal mice and FGB

knock-out mice were applied for tremor record and measurement by 10 mg/kg harmaline injection. Power spectra indicated harmaline induced a severe action tremor with the peak frequency of 8-15 Hz in normal mice, which was dramatically attenuated in FGB knock-out mice, especially maximum tremor motion power (Figures 4C). The maximum tremor motion power was dramatically attenuated in FGB knock-out mice compared with vehicle-treated mice ($P < 0.001$, Figures 4C). Within 10 min duration, there were significant overall tremor activity in harmaline-treated mice compared with vehicle-treated mice ($P < 0.001$), which was significantly blocked in FGB knock-out mice ($P < 0.001$, Figures 4D).

4. Discussion

In this retrospective cohort study, MRgFUS thalamotomy resulted in significant tremor relieve in ET patients, but loss of effectiveness and tremor recurrence has been found in some patients within the follow-up of 12 months. We conducted a thorough profiling of their clinical picture, and key findings include the following: (1) The first evidence regarding fibrinogen-associated di□erences in the ET disease duration, tremor relieve efficiency, and tremor relapse were provided. Additional *in vivo* study identified FGB was highly expressed in human and mice cerebellum and involved in tremor activity. (2) The hypertension comorbidity, especially high admission systolic blood pressure, serves as the independent predictor of tremor recurrence and long-term favorable outcomes. (3) The spectrum of clinical variables was widely expanded based on several criterions of tremor performance not previously reported, and the nomogram models have good predictive power and ability for short-term tremor relieve and long-term tremor recurrence.

So far, the safety of MRgFUS thalamotomy has been widely proven and become increasingly for the patients with various types of tremors in the United States, Japan, South Korea, and China. But research teams have reported a variety of different efficacies of MRgFUS thalamotomy, with mean tremor improve rate ranging from 43% to 83% [14]. Moreover, varying degrees of loss in efficacy and recurrence of tremor were also observed in the long follow-up after treatment. For example, Zaaroor et al has reported that the effect of MRgFUS thalamotomy on tremor was stable over time in most patients (n = 24), with tremor recurring in 6 patients (20%) within the first 6 months [15]. In Hori et al practice of MRgFUS thalamotomy for 12 ET patients, at 1-year follow-up, 8 patients demonstrated relief of tremor, whereas in 4 others tremor recurrence (33%) was noted [7]. However, even with such variable differences and declines in efficacy, there is a lack of a wide accepted standard for the effectiveness of MRgFUS thalamotomy and the criteria for tremor recurrence. Some studies use a 5-point increase in Fahn-Tolosa-Marin rating as a measure of tremor recurrence [6], while others defined as loss of >33% of the efficacy at 3 months relative to a short time after the treatment [16]. Establishment of these consensus as soon as possible is of great significance to further optimize the efficacy of MRgFUS thalamotomy.

At present time, a large number of studies on efficacy pay more attention to the factors of ultrasonic ablation itself, such as ultrasound power, ablation location and size, and so on [16, 17]. This is partly because the identification of the effect of ultrasonic thermal ablation by intraoperative detection technology is still in a preliminary stage. Although previous experience believed that 15s high-intensity

ultrasound was sufficient to cause obvious coagulation necrosis in the target region, various factors led to insufficient energy deposition (such as low SDR) [18, 19]. Instead, recent autopsy studies have reported that the thalamus lesion by MRgFUS was characterized by many foamy macrophages, immunoreactive for CD68 and less for IBA-1, but relatively preserved neurons compared to the adjacent thalamus [19]. In some recurrence cases after MRgFUS thalamotomy, re-ablation or DBS implantation in these patients can still improve their tremor performance again [20-22]. Despite all the above reasons, ignoring the of the disease pathophysiology and the biological features is just an illusion of excitement brought about by technological advance. Previous experience indicated that initially successful radiofrequency thalamotomies can loss effectiveness in up to 15% of cases in the long-term course without any identifiable cause [23].

One key inspiration in our present study was a vital role of fibrinogen in the occurrence and development of ET. Fibrinogen is a pleiotropic protein synthesized by hepatocytes with essential roles in platelet aggregation and hemostasis [24]. More and more studies are beginning to emphasize its unique molecular structure, which contains multiple binding sites for receptors and proteins, resulting in a pluralistic signaling network and pleiotropic functions in neurological disease [24]. For example, in neurodegenerative diseases, fibrinogen not only provides binding sites for toxic substances (such as Aβ and α-synuclein)[25], but also induces microglial activation via CD11b/CD18 to promote initial neuroinflammatory [25]. An overdose of fibrinogen can also hinder neurite outgrowth by acting as a ligand for the β3 integrin receptor on neurons [26], and stimulates the generation of reactive oxygen species and mitochondrial superoxide which causing apoptosis and death [27]. Considering the cerebellar degenerative changes of ET and its high association with PD [28], fibrinogen may also play a vital role in the occurrence and development of ET as well as the tremor symptoms. Although fibrinogen measurement was mainly based on the blood sample in our present study, the Allen brain database strongly suggested its inherent expression in the human brain, especially FGB. Similar fibrinogen labeling on neurons has been observed mulitple times in human and mouse brain tissue samples of AD and MSA [29, 30], but it has been always ignored. In 2019, Gavin et al. confirmed the transcript expression of FGA, FGB and FGG in neurons and astrocytes, and confirmed that they would increased 3-4 times under the stimulation of subarachnoid hemorrhage [31]. Therefore, it is unclear whether tremor suppression in KGB knockout mouse is due to loss of peripheral or central FGB. We are currently conducting further studies to confirm these mechanistic hypotheses.

Another important finding in our present study was the relationship between hypertension and recurrent tremors and long-term favorite outcome. There are at least three hypotheses for it: (1) The hypertension mechanisms may be involved in the occurrence and maintenance of tremor diseases and symptoms. Studies have presented that the difference in the prevalence of hypertension between ET and non-ET patients is more than 10%, and in some ET patient cohort [32], the prevalence of hypertension was over 70% [33]. Meta-analysis for PD risk factors found that the total RR was 1.70 [34], and there was a significant coupling between the intensity of tremor and the severity of hypertension [35]. ET patients had significantly reduced catecholamine metabolism and excretion [36], and some case reports indicated adverse effects of severe tremor in patients when treated with beta-blockers [37]. (2) Alteration cerebral stiffness due to hypertension may lead to decreased energy convergence of transcranial

ultrasound. It has been well proven that the ultrasound transmission is closely related to the medium characteristics. Long-term hypertension can lead to microcirculation dysfunction [24], which subsequently leads to the alteration in gray matter microstructure [25], the overload of cerebral blood flow and cerebrospinal fluid circulation [26]. These alterations can be sensitively captured in diagnostic ultrasound such as time-harmonic ultrasound elastography, so whether there is an impact on high-intensity focused ultrasound is currently unclear. (3) The hypertension may also impact on the long-term brain remodeling after minor brain lesion therapy such as thalamectomy. Our series of works have demonstrated topological changes in regional structural and functional connectivity networks due to Vim lesion and potential dopaminergic mechanisms. Considering hypertension has always been regarded as a kind of adverse prognostic factor for brain injury, and it may have a significant impact on long-term recovery after treatment. To sum up, the influence and mechanism of hypertension for MRgFUS thalamotomy holds a lot of areas for we to further explore.

Several methodological considerations should be contemplated when interpreting the results of this study. First, our study mainly used the clinical examination results during their hospitalization for MRgFUS thalamotomy. Lack of clinical examination at the follow-up timepoints and not considering drug use may lead to biased interpretation for current results. Second, a small number of patients with extreme tremor may lead to low statistical power considering subjects' heterogeneity. It is important to carry out a multi-center retrospective study or a prospective study to further confirm these research findings. Third, the AHBA/AMBA transcriptome data were obtained from health participants/mice without specificity of ET disease pathophysiology. The FGB knockout were not tissue-selective so that further validation require cerebellum-specific FBG knockouts.

In conclusion, our study demonstrated for the first time the difference in biological variables of prognostic differences in ET patients treated with MRgFUS thalamotomy, and suggested fibrinogen and hypertension as the key factors affecting short-term tremor relieve, tremor recurrence, and long-term favorite outcome. Special attention should be paid to recommendations for ET patients with the above two risk factors when preparing for MRgFUS thalamotomy, in order to minimize potential loss of efficiency for them.

5. References

1. Yamamoto, K., et al., *Magnetic resonance-guided focused ultrasound for the treatment of tremor.* Expert Rev Neurother, 2022. **22**(10): p. 849-861.

2. Schlesinger, I., A. Sinai, and M.J.P.s.D. Zaaroor, *MRI-guided focused ultrasound in Parkinson's disease: a review.* 2017. **2017**.

3. Jameel, A., et al., *The cost-effectiveness of unilateral magnetic resonance-guided focused ultrasound in comparison with unilateral deep brain stimulation for the treatment of medically refractory essential tremor in England.* Br J Radiol, 2022. **95**(1140): p. 20220137.

4. Elias, W.J., et al., *A Randomized Trial of Focused Ultrasound Thalamotomy for Essential Tremor.* N Engl J Med, 2016. **375**(8): p. 730-9.

5. Wang, T.R., et al., *Thalamic Deep Brain Stimulation Salvages Failed Focused Ultrasound Thalamotomy for Essential Tremor: A Case Report.* Stereotact Funct Neurosurg, 2018. **96**(1): p. 60-64.

6. Bruno, F., et al., *Comprehensive Evaluation of Factors Affecting Tremor Relapse after MRgFUS Thalamotomy: A Case-Control Study.* Brain Sci, 2021. **11**(9).

7. Hori, H., et al., *Correlation between fractional anisotropy changes in the targeted ventral intermediate nucleus and clinical outcome after transcranial MR-guided focused ultrasound thalamotomy for essential tremor: results of a pilot study.* J Neurosurg, 2019. **132**(2): p. 568-573.

8. Maas, A.I.R., et al., *Traumatic brain injury: progress and challenges in prevention, clinical care, and research.* Lancet Neurol, 2022. **21**(11): p. 1004-1060.

9. Lin, J., et al., *Convergent structural network and gene signatures for MRgFUS thalamotomy in patients with Parkinson's disease.* Neuroimage, 2021. **243**: p. 118550.

10. Pae, C., et al., *Differences in intrinsic functional networks in patients with essential tremor who had good and poor long-term responses after thalamotomy performed using MR-guided ultrasound.* J Neurosurg, 2023. **138**(2): p. 318-328.

11. Hawrylycz, M.J., et al., *An anatomically comprehensive atlas of the adult human brain transcriptome.* Nature, 2012. **489**(7416): p. 391-399.

12. Liang, Z., et al., *Virtual mouse brain histology from multi-contrast MRI via deep learning.* Elife, 2022. **11**.

13. Markello, R.D., et al., *Standardizing workflows in imaging transcriptomics with the abagen toolbox.* Elife, 2021. **10**.

14. Maesawa, S., et al., *Techniques, Indications, and Outcomes in Magnetic Resonance-guided Focused Ultrasound Thalamotomy for Tremor.* Neurol Med Chir (Tokyo), 2021. **61**(11): p. 629-639.

15. Zaaroor, M., et al., *Magnetic resonance-guided focused ultrasound thalamotomy for tremor: a report of 30 Parkinson's disease and essential tremor cases.* J Neurosurg, 2018. **128**(1): p. 202-210.

16. Kapadia, A.N., et al., *Multimodal MRI for MRgFUS in essential tremor: post-treatment radiological markers of clinical outcome.* J Neurol Neurosurg Psychiatry, 2020. **91**(9): p. 921-927.

17. Xiong, Y., et al., *Pretherapeutic functional connectivity of tractography-based targeting of the ventral intermediate nucleus for predicting tremor response in patients with Parkinson's disease after thalamotomy with MRI-guided focused ultrasound.* J Neurosurg, 2022: p. 1-10.

18. McDannold, N., et al., *MRI investigation of the threshold for thermally induced blood-brain barrier disruption and brain tissue damage in the rabbit brain.* Magn Reson Med, 2004. **51**(5): p. 913-23.

19. Koga, S., et al., *Neuropathology of Parkinson's disease after focused ultrasound thalamotomy.* NPJ Parkinsons Dis, 2022. **8**(1): p. 59.

20. Levi, V., et al., *Is Deep Brain Stimulation still an option for tremor recurrence after Focused Ultrasound thalamotomy? A case report.* J Clin Neurosci, 2019. **68**: p. 344-346.

21. De Vloo, P., et al., *Microelectrode Recording and Radiofrequency Thalamotomy following Focused Ultrasound Thalamotomy.* Stereotact Funct Neurosurg, 2021. **99**(1): p. 34-37.

22. Weidman, E.K., et al., *Repeat magnetic resonance imaging-guided focused ultrasound thalamotomy for recurrent essential tremor: case report and review of MRI findings.* J Neurosurg, 2019: p. 1-6.

23. Linhares, M.N. and R.R. Tasker, *Microelectrode-guided thalamotomy for Parkinson's disease.* Neurosurgery, 2000. **46**(2): p. 390-5; discussion 395-8.

24. Petersen, M.A., J.K. Ryu, and K. Akassoglou, *Fibrinogen in neurological diseases: mechanisms, imaging and therapeutics.* Nat Rev Neurosci, 2018. **19**(5): p. 283-301.

25. Wen, T. and Z. Zhang, *Cellular mechanisms of fibrin (ogen): insight from neurodegenerative diseases.* Front Neurosci, 2023. **17**: p. 1197094.

26. Schachtrup, C., et al., *Fibrinogen inhibits neurite outgrowth via beta 3 integrin-mediated phosphorylation of the EGF receptor.* Proc Natl Acad Sci U S A, 2007. **104**(28): p. 11814-9.

27. Sulimai, N., J. Brown, and D. Lominadze, *The Effects of Fibrinogen's Interactions with Its Neuronal Receptors, Intercellular Adhesion Molecule-1 and Cellular Prion Protein.* Biomolecules, 2021. **11**(9).

28. Yoo, S.W., et al., *Exploring the link between essential tremor and Parkinson's disease.* NPJ Parkinsons Dis, 2023. **9**(1): p. 134.

29. Bian, Z., et al., *Accelerated accumulation of fibrinogen peptide chains with Aβ deposition in Alzheimer's disease (AD) mice and human AD brains.* Brain Res, 2021. **1767**: p. 147569.

30. Rydbirk, R., et al., *Brain proteome profiling implicates the complement and coagulation cascade in multiple system atrophy brain pathology.* Cell Mol Life Sci, 2022. **79**(6): p. 336.

31. Golanov, E.V., et al., *Fibrinogen Chains Intrinsic to the Brain.* Front Neurosci, 2019. **13**: p. 541.

32. Louis, E.D., *Increased Medical Comorbidities in Essential Tremor-A Wake-up Call?* J Health Econ Outcomes Res, 2022. **9**(2): p. 123-124.

33. Dai, D., et al., *Multiple Comorbidities, Psychiatric Disorders, Healthcare Resource Utilization and Costs Among Adults with Essential Tremor: A Retrospective Observational Study in a Large US Commercially Insured and Medicare Advantage Population.* J Health Econ Outcomes Res, 2022. **9**(2): p. 37-46.

34. Chen, J., et al., *Association between Hypertension and the Risk of Parkinson's Disease: A Meta-Analysis of Analytical Studies.* Neuroepidemiology, 2019. **52**(3-4): p. 181-192.

35. Morrison, S., et al., *Aging, hypertension and physiological tremor: the contribution of the cardioballistic impulse to tremorgenesis in older adults.* J Neurol Sci, 2013. **326**(1-2): p. 68-74.

36. Barkhatova, V.P. and I.A. Ivanova-Smolenskaia, *[Catecholamine metabolism in essential tremor].* Zh Nevropatol Psikhiatr Im S S Korsakova, 1990. **90**(3): p. 10-4.

37. Al-Shorafat, D.M., et al., *β-Blocker-Induced Tremor.* Mov Disord Clin Pract, 2021. **8**(3): p. 449-452.

Figure Legend

Figure 1 Factors associated with better tremor relieve in ET patients right after unilateral MRgFUS thalamotomy

(A) Relative ratio of tremor ratings in ET patients subjected with MRgFUS thalamotomy. **(B)** Nomogram predicting the better efficiency in tremor relieve (control ratio > 75%) probabilities of ET right after MRgFUS thalamotomy. **(C)** The ROC curves represent the discrimination ability of the model measured by the AUC is 0.820. (Pre-op = pre-operative; 1-month = 1-month postoperatively; 3- month = 3-month postoperatively; 6-month = 6-month postoperatively; 12-month = 12-month postoperatively. Comparison with Pre-op: $^{***}P < 0.001$.)

Figure 2 Factors associated with tremor recurrence in ET patients with unilateral MRgFUS thalamotomy

(A) The temporal change of relative hand tremor control ratio in each ET patient with tremor recurrence within the follow-up of 12 month after MRgFUS thalamotomy. **(B)** Nomogram predicting the tremor recurrency probabilities of ET patients within the follow-up of 12 month after MRgFUS thalamotomy. **(C)** The ROC curves represent the discrimination ability of the model measured by the AUC is 0.829. (Pre-op = pre-operative; 1-month = 1-month postoperatively; 3-month = 3-month postoperatively; 6-month = 6-month postoperatively; 12-month = 12-month postoperatively; ASBP = admission systolic blood pressure.)

Figure 3 Factors associated with long-term favorable outcome in ET Patients with unilateral MRgFUS thalamotomy

(A) The temporal change of relative hand tremor control ratio in each ET patient with long-term favorable outcome within the follow-up of 12 month after MRgFUS thalamotomy.   **(B)** The ROC curves represent the discrimination ability of the model measured by the AUC is 0.853. (Pre-op = pre-operative; 1-month = 1-month postoperatively; 3- month = 3-month postoperatively; 6-month = 6-month postoperatively; 12-month = 12-month postoperatively.)

Figure 4 Suppression of Fibrinogen beta knock-out on harmaline-induced tremor *in vivo*

(A) Human FGB expression based on AHBA. (CC: cerebral cortex, BG: basal ganglia, Tha: thalamus, CB: cerebellum. Comparison with CB: $^{*}P < 0.05$, $^{***}P < 0.001$) **(B)** Mouse RNA ISH expression based on AMBA. **(C)** Power spectra for tremor. (FGB KO: in the FGB knock-out mice. Comparison with Harmaline: $^{***}P < 0.001$, n = 12.) **(D)** Tremor activity. (FGB KO: in the FGB knock-out mice. Comparison with Vehicle: $^{***}P < 0.001$, n = 12. Comparison with Harmaline: $^{\#\#\#}P < 0.001$, n = 12.)

Table 1. Comparison of demographic and clinical features of ET patients with or without better tremor relieve

Clinical features	Total cohort	With better tremor relieve (n = 39)	Without better tremor relieve (n = 20)	*p* value
Demographic characteristics				
Age	62.914(9.802)	63.550(10.231)	62.579(9.692)	-
Gender	42:17	25:14	17:3	-
Body mass index (BMI)	24.758(3.194)	24.275(2.850)	25.019(3.373)	-
Admission systolic blood pressure	135.193(18.654)	141.700(18.810)	131.676(17.842)	-
Admission diastolic blood pressure	82.737(11.116)	86.450(11.958)	80.730(10.243)	-
Pulse rate	80.07(9.083)	82.950(8.494)	78.514(9.118)	-
Comorbidity				
Hypertension (with:without)	22:37	15:24	7:13	-
Diabetes (with:without)	11:48	9:30	2:18	-
Hyperlipemia (with:without)	15:44	8:31	7:13	-
Hematological analysis				
Hemoglobin	143.915(16.504)	142.900(17.823)	144.436(16.003)	-
Red blood cell count	4.666(0.550)	4.728(0.643)	4.635(0.501)	-
White blood cell count	5.852(1.250)	6.049(1.154)	5.751(1.299)	-
Neutrophil count	0.556(0.075)	0.541(0.079)	0.563(0.072)	-
Lymphocyte count	0.344(0.066)	0.351(0.076)	0.340(0.062)	-
Monocyte count	0.071(0.017)	0.078(0.019)	0.068(0.015)	0.025
Eosinophil count	0.024(0.018)	0.024(0.019)	0.024(0.017)	-
Basophil count	0.006(0.003)	0.007(0.004)	0.005(0.003)	0.004
Hematocrit	0.422(0.042)	0.422(0.044)	0.422(0.042)	-
Mean corpuscular volume	90.902(5.919)	90.085(8.623)	91.321(3.972)	-
Mean corpusular hemoglobin	30.953(2.398)	30.490(3.535)	31.190(1.535)	-
Mean corpusular hemoglobin concerntration	340.356(14.699)	338.000(18.770)	341.564(12.215)	-
Red blood cell volume distribution	12.808(1.490)	13.090(2.344)	12.664(0.761)	-
Platelet count	220.559(62.940)	228.500(52.796)	216.487(67.841)	-
Mean platelet volume	10.354(0.879)	10.315(0.783)	10.374(0.934)	-
Coagulation function				
Thrombin time	17.260(1.032)	17.385(0.612)	17.195(1.198)	-
Activated partial thromboplastin time	33.359(4.376)	32.875(4.556)	33.608(4.320)	-
Prothrombin time	12.393(1.042)	12.260(1.169)	12.462(0.979)	-
Prothrombin Activity	105.803(13.651)	108.530(16.007)	104.405(12.263)	-
International normalized ratio	0.978(0.068)	0.965(0.079)	0.985(0.062)	-
Fibrinogen	2.881(0.550)	3.116(0.669)	2.761(0.441)	0.025
Blood biochemistry				
Alanine aminotransferase	18.900(9.551)	19.560(10.135)	18.562(9.356)	-
Aspartate aminotransferase	20.102(7.369)	21.280(8.176)	19.497(6.953)	-

Total protein	70.878(5.268)	72.830(4.993)	69.850(5.178)	0.027
Serum albumin	44.729(3.470)	45.505(3.415)	44.321(3.473)	-
Total bilirubin	13.114(7.375)	13.73(10.562)	12.772(4.957)	-
Direct bilirubin	4.279(2.560)	4.630(3.545)	4.083(1.834)	-
Total bile acids	5.036(7.181)	6.532(11.17)	4.268(3.823)	-
Homocysteine	20.574(17.654)	26.894(24.900)	16.442(9.049)	-
Alkaline phosphatase	71.700(17.754)	79.71(20.668)	67.484(14.604)	0.008
Gamma-glutamyltransferase	29.712(40.692)	40.84(59.635)	23.855(24.951)	-
Glucose	5.887(1.801)	6.072(1.802)	5.792(1.817)	-
Urea	5.776(1.653)	5.905(2.117)	5.710(1.385)	-
Serum creatinine	80.200(17.410)	83.140(18.648)	78.692(16.789)	-
Serum uric acid	331.273(89.978)	324.805(90.012)	334.590(90.954)	-
Lactate dehydrogenase	172.518(47.147)	163.9(31.590)	177.306(53.715)	-
Total iron-binding capacity	51.555(6.569)	50.95(7.566)	51.689(6.831)	-
Creatine kinase	119.796(133.274)	129.14(204.777)	114.606(71.204)	-
Creatine kinase isoenzyme	18.946(18.415)	16.322(3.894)	20.632(23.412)	-
Serum calcium	2.319(0.116)	2.352(0.106)	2.302(0.118)	-
Inorganic phosphorus	1.114(0.138)	1.121(0.161)	1.111(0.127)	-
Serum magnesium	0.881(0.070)	0.887(0.081)	0.879(0.064)	-
Serum kalium	4.159(0.373)	4.203(0.462)	4.137(0.323)	-
Serum sodium	141.956(2.174)	141.395(2.599)	142.244(1.893)	-
Serum chloride	103.902(2.374)	103.515(2.638)	104.100(2.236)	-
Serum Carbon dioxide	26.684(2.206)	26.600(2.304)	26.730(2.183)	-
Serum superoxide dismutase	175.449(29.865)	182.312(41.271)	170.588(17.518)	-
Phospholipid	2.513(0.411)	2.217(0.302)	2.588(0.410)	-
Glycosylated serum protein	195.025(55.906)	203.511(61.975)	190.282(52.587)	-
Serum Cystatin C	0.972(0.186)	0.999(0.215)	0.953(0.164)	-
Serum sialic acid	56.438(6.593)	57.575(7.531)	55.679(5.935)	-
Glycated albumin	15.646(3.799)	15.794(4.660)	15.521(3.021)	-
α-L-fucosidase	28.823(6.176)	29.381(5.274)	28.450(6.796)	-
Glycholic acid	1.396(2.169)	1.953(3.534)	1.080(0.532)	-
Cholesterol	4.625(0.848)	4.846(0.807)	4.505(0.858)	-
Triglyceride	1.630(1.586)	2.059(2.354)	1.397(0.909)	-
Apolipoprotein A1	1.417(0.244)	1.435(0.213)	1.407(0.263)	-
Apolipoprotein B	0.822(0.162)	0.848(0.165)	0.807(0.161)	-
High-density lipoprotein cholestero	1.287(0.339)	1.285(0.375)	1.289(0.324)	-
Low-density lipoprotein cholesterol	3.048(0.737)	3.157(0.745)	2.987(0.736)	-
Serum lipoprotein (a)	17.278(18.939)	21.711(27.744)	14.872(11.606)	-

Note: Results were expressed as Mean ± SD. Intergroup differences were evaluated by chi-square or Fisher exact tests for categorical data and by Student t-test or Mann-Whitney U test for continuous data with normal or skew distribution. Only $P < 0.05$ would be shown in table.

Table 2. Logistic regression analysis of factors associated with better tremor relieve in ET patients subjected with MRgFUS thalamotomy

Clinical features	Univariate analysis		Multivariate analysis	
	OR (95% CI)	*P* value	OR (95% CI)	*P* value
Monocyte count	0(0-0.011)	0.027	0(0-0.001)	0.014
Basophil count	0(0-0.001)	0.026	0(0-2×10^6)	0.069
Fibrinogen	0.292(0.096-0.886)	0.030	0.182(0.042-0.796)	0.024
Total protein	0.891(0.794-0.999)	0.044	0.095(0.760-1.022)	0.095
Alkaline phosphatase	0.956(0.922-0.992)	0.016	0.978(0.936-1.021)	0.311

Note: OR = odds ratio, CI = confidence interval. Only the items with $P < 0.05$ in the univariate analysis were used for the subsequent multivariate analysis.

Table 3. Comparison of demographic and clinical features of ET patients with or without tremor recurrence

Clinical features	Total cohort	With tremor recurrence (n = 9)	Without tremor recurrence (n = 50)	*P* value
Demographic characteristics				
Age	62.914(9.802)	69.556(4.503)	61.694(10.046)	0.026
Gender (male:female)	42:17	7:2	35:15	-
Body mass index (BMI)	24.758(3.194)	24.733(3.068)	24.763(3.248)	-
Admission systolic blood pressure	135.193(18.654)	146.111(18.871)	133.146(16.702)	0.040
Admission diastolic blood pressure	82.737(11.116)	87.778(14.140)	81.792(10.364)	-
Pulse rate	80.070(9.083)	76.444(6.710)	80.750(9.362)	-
Comorbidity				
Hypertension (with:without)	22:37	7:2	15:35	0.006
Diabetes (with:without)	11:48	0:9	11:39	-
Hyperlipemia (with:without)	15:44	2:7	13:37	-
Hematological analysis				
Hemoglobin	143.915(16.504)	145.333(18.412)	143.66(16.329)	-
Red blood cell count	4.666(0.550)	4.741(0.632)	4.653(0.540)	-
White blood cell count	5.852(1.250)	6.182(1.341)	5.793(1.237)	-
Neutrophil count	0.556(0.075)	0.551(0.059)	0.557(0.078)	-
Lymphocyte count	0.344(0.066)	0.35(0.064)	0.342(0.067)	-
Monocyte count	0.071(0.017)	0.074(0.011)	0.071(0.018)	-
Eosinophil count	0.024(0.018)	0.021(0.011)	0.024(0.018)	-
Basophil count	0.006(0.003)	0.005(0.003)	0.006(0.003)	-
Hematocrit	0.422(0.042)	0.43(0.047)	0.421(0.042)	-
Mean corpuscular volume	90.902(5.919)	90.978(3.224)	90.888(6.307)	-
Mean corpusular hemoglobin	30.953(2.398)	30.711(1.949)	30.996(2.485)	-
Mean corpusular hemoglobin concerntration	340.356(14.699)	337.556(16.471)	340.860(14.483)	-
Red blood cell volume distribution	12.808(1.490)	13.456(1.329)	12.692(1.500)	-
Platelet count	220.559(62.940)	216.333(46.441)	221.320(65.826)	-
Mean platelet volume	10.354(0.879)	10.144(0.868)	10.392(0.885)	-
Coagulation function				
Thrombin time	17.260(1.032)	17.378(0.763)	17.239(1.079)	-
Activated partial thromboplastin time	33.359(4.376)	34.511(4.939)	33.152(4.289)	-
Prothrombin time	12.393(1.042)	12.089(0.909)	12.448(1.063)	-
Prothrombin Activity	105.803(13.651)	112.222(14.793)	104.648(13.263)	-
International normalized ratio	0.978(0.068)	0.964(0.051)	0.980(0.071)	-
Fibrinogen	2.881(0.550)	3.250(0.693)	2.815(0.501)	0.028
Blood biochemistry				
Alanine aminotransferase	18.900(9.551)	20.433(9.539)	18.624(9.624)	-
Aspartate aminotransferase	20.102(7.369)	20.900(6.878)	19.958(7.511)	-
Total protein	70.878(5.268)	70.922(5.547)	70.869(5.275)	-

Serum albumin	44.729(3.470)	44.044(3.628)	44.855(3.464)	-
Total bilirubin	13.114(7.375)	16.311(13.129)	12.502(5.715)	-
Direct bilirubin	4.279(2.560)	5.200(4.226)	4.102(2.128)	-
Total bile acids	5.036(7.181)	4.822(3.176)	5.077(7.739)	-
Homocysteine	20.574(17.654)	24.413(23.228)	19.697(16.421)	-
Alkaline phosphatase	71.700(17.754)	80.689(21.203)	70.049(16.776)	-
Gamma-glutamyltransferase	29.712(40.692)	31.222(30.497)	29.435(42.553)	-
Glucose	5.887(1.801)	5.722(1.073)	5.916(1.910)	-
Urea	5.776(1.653)	6.703(2.746)	5.609(1.348)	-
Serum creatinine	80.200(17.410)	85.778(21.094)	79.196(16.715)	-
Serum uric acid	331.273(89.978)	342.222(85.714)	329.302(91.42)	-
Lactate dehydrogenase	172.518(47.147)	180.289(32.911)	171.03(49.551)	-
Total iron-binding capacity	51.555(6.569)	47.75(3.041)	52.4(6.954)	-
Creatine kinase	119.796(133.274)	141.789(117.652)	115.585(136.810)	-
Creatine kinase isoenzyme	18.946(18.415)	16.556(7.111)	19.527(20.270)	-
Serum calcium	2.319(0.116)	2.287(0.126)	2.325(0.114)	-
Inorganic phosphorus	1.114(0.138)	1.169(0.120)	1.104(0.140)	-
Serum magnesium	0.881(0.070)	0.924(0.056)	0.873(0.070)	0.045
Serum kalium	4.159(0.373)	4.074(0.366)	4.175(0.376)	-
Serum sodium	141.956(2.174)	141.444(3.319)	142.048(1.933)	-
Serum chloride	103.902(2.374)	104(2.653)	103.884(2.349)	-
Serum Carbon dioxide	26.684(2.206)	26.167(2.893)	26.781(2.077)	-
Serum superoxide dismutase	175.449(29.865)	169.063(20.353)	176.997(31.806)	-
Phospholipid	2.513(0.411)	2.18(0.173)	2.597(0.414)	-
Glycosylated serum protein	195.025(55.906)	180.356(26.765)	198.025(59.935)	-
Serum Cystatin C	0.972(0.186)	1.043(0.178)	0.955(0.186)	-
Serum sialic acid	56.438(6.593)	59.888(5.475)	55.575(6.640)	-
Glycated albumin	15.646(3.799)	14.7(2.017)	15.841(4.070)	-
α-L-fucosidase	28.823(6.176)	28.938(5.492)	28.794(6.417)	-
Glycholic acid	1.396(2.169)	1.2(0.466)	1.436(2.376)	-
Cholesterol	4.625(0.848)	5.009(1.038)	4.548(0.797)	-
Triglyceride	1.630(1.586)	1.411(0.933)	1.674(1.691)	-
Apolipoprotein A1	1.417(0.244)	1.438(0.299)	1.413(0.235)	-
Apolipoprotein B	0.822(0.162)	0.913(0.159)	0.802(0.158)	-
High-density lipoprotein cholestero	1.287(0.339)	1.379(0.446)	1.271(0.319)	-
Low-density lipoprotein cholesterol	3.048(0.737)	3.462(0.673)	2.963(0.727)	-
Serum lipoprotein (a)	17.278(18.939)	28.764(33.865)	14.981(13.826)	0.045

Note: Results were expressed as Mean ± SD. Intergroup differences were evaluated by chi-square or Fisher exact tests for categorical data and by Student t-test or Mann-Whitney U test for continuous data with normal or skew distribution. Only $P < 0.05$ would be shown in table.

Table 4. Logistic regression analysis of factors associated with tremor recurrence in ET patients subjected with MRgFUS thalamotomy

Clinical features	Univariate analysis		Multivariate analysis	
	OR (95% CI)	*P* value	OR (95% CI)	*P* value
Age	1.143(1.012-1.290)	0.032	1.118(0.925-1.351)	0.250
Admission systolic blood pressure	1.053(1.036-1.075)	0.046	1.013(1.010-1.062)	0.049
Hypertension	7.7(1.427-41.557)	0.018	2.163(1.412-53.565)	0.020
Fibrinogen	4.255(1.091-16.597)	0.037	1.620(1.047-24.376)	0.044
Serum magnesium	$6\times10^5(1.076\text{-}4\times10^{11})$	0.049	$6\times10^5(0.016\text{-}2\times10^{11})$	0.540
Serum lipoprotein (a)	1.031(0.995-1.067)	0.097	-	-

Note: OR = odds ratio, CI = confidence interval. Only the items with $P < 0.05$ in the univariate analysis were used for the subsequent multivariate analysis.

Table 5. Comparison of demographic and clinical features of ET patients with or without favorable outcome

Clinical features	Total cohort	With favorable outcome (n = 15)	Without favorable outcome (n = 44)	*p* value
Demographic characteristics				
Age	62.914(9.802)	58.533(11.230)	64.442(8.894)	0.043
Gender (male:female)	15:44	10:5	5:39	-
Body mass index (BMI)	24.758(3.194)	24.100(2.782)	24.993(3.328)	-
Admission systolic blood pressure	135.193(18.654)	119.667(11.299)	140.738(17.664)	< 0.001
Admission diastolic blood pressure	82.737(11.116)	76.667(10.175)	84.905(10.729)	0.012
Pulse rate	80.070(9.083)	79.533(11.600)	80.262(8.160)	-
Comorbidity				
Hypertension (with:without)	11:48	4(11)	7(37)	-
Diabetes (with:without)	11:48	4(11)	7(37)	-
Hyperlipemia (with:without)	15:44	3(12)	12(32)	-
Hematological analysis				
Hemoglobin	143.915(16.504)	147.600(16.208)	142.659(16.599)	-
Red blood cell count	4.666(0.550)	4.771(0.465)	4.630(0.576)	-
White blood cell count	5.852(1.250)	5.407(1.036)	6.004(1.290)	-
Neutrophil count	0.556(0.075)	0.563(0.077)	0.553(0.075)	-
Lymphocyte count	0.344(0.066)	0.34(0.065)	0.345(0.068)	-
Monocyte count	0.071(0.017)	0.068(0.012)	0.072(0.019)	-
Eosinophil count	0.024(0.018)	0.024(0.017)	0.024(0.018)	-
Basophil count	0.006(0.003)	0.005(0.003)	0.006(0.003)	-
Hematocrit	0.422(0.042)	0.433(0.041)	0.419(0.043)	-
Mean corpuscular volume	90.902(5.919)	90.9(4.072)	90.902(6.470)	-
Mean corpusular hemoglobin	30.953(2.398)	30.92(1.043)	30.964(2.720)	-
Mean corpusular hemoglobin concerntration	340.356(14.699)	340.333(12.327)	340.364(15.555)	-
Red blood cell volume distribution	12.808(1.490)	12.56(0.81)	12.893(1.659)	-
Platelet count	220.559(62.940)	204.933(56.086)	225.886(64.846)	-
Mean platelet volume	10.354(0.879)	10.573(1.021)	10.28(0.825)	-
Coagulation function				
Thrombin time	17.260(1.032)	17.340(1.206)	17.233(0.979)	-
Activated partial thromboplastin time	33.359(4.376)	32.753(4.388)	33.566(4.403)	-
Prothrombin time	12.393(1.042)	12.373(0.900)	12.4(1.095)	-
Prothrombin Activity	105.803(13.651)	104.813(11.812)	106.141(14.334)	-
International normalized ratio	0.978(0.068)	0.977(0.065)	0.978(0.070)	-
Fibrinogen	2.881(0.550)	2.6600.5(0.554)	2.956(0.535)	-
Blood biochemistry				
Alanine aminotransferase	18.900(9.551)	17.393(6.844)	19.414(10.331)	-
Aspartate aminotransferase	20.102(7.369)	18.973(5.400)	20.486(7.947)	-

Total protein	70.878(5.268)	69.521(6.067)	71.309(4.987)	-
Serum albumin	44.729(3.470)	43.543(3.416)	45.107(3.439)	-
Total bilirubin	13.114(7.375)	13.379(5.096)	13.026(8.043)	-
Direct bilirubin	4.279(2.560)	4.357(2.035)	4.252(2.734)	-
Total bile acids	5.036(7.181)	5.223(4.981)	4.979(7.774)	-
Homocysteine	20.574(17.654)	18.289(11.462)	21.179(19.053)	-
Alkaline phosphatase	71.700(17.754)	61.886(11.870)	74.823(18.272)	0.016
Gamma-glutamyltransferase	29.712(40.692)	19.357(6.858)	33.007(46.203)	-
Glucose	5.887(1.801)	5.782(2.363)	5.923(1.598)	-
Urea	5.776(1.653)	5.281(1.256)	5.945(1.749)	-
Serum creatinine	80.200(17.410)	79.993(22.405)	80.270(15.664)	-
Serum uric acid	331.273(89.978)	339.987(108.439)	328.302(84.001)	-
Lactate dehydrogenase	172.518(47.147)	181.100(76.423)	169.657(33.113)	-
Total iron-binding capacity	51.555(6.569)	48.633(7.021)	52.650(6.521)	-
Creatine kinase	119.796(133.274)	88.493(45.574)	130.231(150.739)	-
Creatine kinase isoenzyme	18.946(18.415)	14.36(6.272)	20.219(20.450)	-
Serum calcium	2.319(0.116)	2.277(0.136)	2.332(0.107)	-
Inorganic phosphorus	1.114(0.138)	1.112(0.121)	1.115(0.144)	-
Serum magnesium	0.881(0.070)	0.876(0.065)	0.883(0.072)	-
Serum kalium	4.159(0.373)	4.212(0.302)	4.142(0.396)	-
Serum sodium	141.956(2.174)	142.113(1.895)	141.902(2.278)	-
Serum chloride	103.902(2.374)	103.593(2.955)	104.007(2.171)	-
Serum Carbon dioxide	26.684(2.206)	26.677(1.464)	26.686(2.396)	-
Serum superoxide dismutase	175.449(29.865)	162.025(17.57)	178.703(31.487)	-
Phospholipid	2.513(0.411)	2.453(0.165)	2.528(0.457)	-
Glycosylated serum protein	195.025(55.906)	199.6(65.504)	193.96(54.259)	-
Serum Cystatin C	0.972(0.186)	0.918(0.196)	0.985(0.184)	-
Serum sialic acid	56.438(6.593)	55.125(5.487)	56.766(6.880)	-
Glycated albumin	15.646(3.799)	15.243(3.097)	15.746(3.999)	-
α-L-fucosidase	28.823(6.176)	26.8(6.129)	29.328(6.180)	-
Glycholic acid	1.396(2.169)	1.23(0.558)	1.441(2.433)	-
Cholesterol	4.625(0.848)	4.242(0.709)	4.723(0.860)	-
Triglyceride	1.630(1.586)	1.331(0.512)	1.707(1.755)	-
Apolipoprotein A1	1.417(0.244)	1.410(0.267)	1.419(0.241)	-
Apolipoprotein B	0.822(0.162)	0.721(0.152)	0.849(0.156)	0.019
High-density lipoprotein cholestero	1.287(0.339)	1.314(0.294)	1.281(0.351)	-
Low-density lipoprotein cholesterol	3.048(0.737)	2.763(0.683)	3.114(0.740)	-
Serum lipoprotein (a)	17.278(18.939)	16.195(12.351)	17.555(20.394)	-

Note: Results were expressed as Mean ± SD. Intergroup differences were evaluated by chi-square or Fisher exact tests for categorical data and by Student t-test or Mann-Whitney U test for continuous data with normal or skew distribution. Only $P < 0.05$ would be shown in table.

Table 6. Logistic regression analysis of factors associated with favorable outcomes in ET patients subjected with MRgFUS thalamotomy

Clinical features	Univariate analysis		Multivariate analysis	
	OR (95% CI)	*P* value	OR (95% CI)	*P* value
Age	0.941(0.885-1.001)	0.054	-	-
Admission systolic blood pressure	0.881(0.816-0.952)	0.001	0.880(0.785-0.987)	0.029
Admission diastolic blood pressure	0.925(0.867-0.987)	0.019	1.031(0.923-1.153)	0.586
Apolipoprotein B	0.003(0-0.512)	0.027	0.054(0-35.467)	0.377
Alkaline phosphatase	0.949(0.908-0.993)	0.022	0.960(0.906-1.017)	0.166
Fibrinogen	0.326(0.094-1.132)	0.078	-	-

Note: OR = odds ratio, CI = confidence interval. Only the items with $P < 0.05$ in the univariate analysis were used for the subsequent multivariate analysis.

A Human FGB expression based on AHBA

B Mouse RNA ISH expression based on AMBA